US20210024623A1 - Anti-bag3 antibodies as therapeutic reagent in cardiovascular disease - Google Patents

Anti-bag3 antibodies as therapeutic reagent in cardiovascular disease Download PDF

Info

Publication number
US20210024623A1
US20210024623A1 US17/040,468 US201817040468A US2021024623A1 US 20210024623 A1 US20210024623 A1 US 20210024623A1 US 201817040468 A US201817040468 A US 201817040468A US 2021024623 A1 US2021024623 A1 US 2021024623A1
Authority
US
United States
Prior art keywords
seq
bag3
antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/040,468
Other languages
English (en)
Inventor
Maria Caterina Turco
Liberato MARZULLO
Alessandra ROSATI
Margot DE MARCO
Anna BASILE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrosys Srl
Intrepida Bio Inc
Original Assignee
Intrepida Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT102017000113648A external-priority patent/IT201700113648A1/it
Application filed by Intrepida Bio Inc filed Critical Intrepida Bio Inc
Publication of US20210024623A1 publication Critical patent/US20210024623A1/en
Assigned to BIOUNIVERSA S.R.L. reassignment BIOUNIVERSA S.R.L. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BASILE, Anna, DE MARCO, Margot, MARZULLO, Liberato, ROSATI, Alessandra, TURCO, MARIA CATERINA
Assigned to FIBROSYS S.R.L. reassignment FIBROSYS S.R.L. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIOUNIVERSA S.R.L.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Definitions

  • the present invention relates to the use of anti-BAG3 antibodies and its pharmaceutical formulation in the treatment of cardiovascular diseases.
  • BAG3 protein is a 74 kDa cytoplasmic protein which belongs to the family of co-chaperons that interact with the ATPase domain of the protein HSP70 (Heat Shock Protein) through the structural domain known as the BAG domain (amino acids 110-124). Furthermore, BAG3 protein contains a WW domain (Trp-Trp), a proline-rich region (PXXP), and two conserved motifs IPV (IIe-Pro-Val), which can mediate binding to other proteins. Thanks to the nature of BAG3 protein as an adapter, attributable to the presence of many functional domains, such protein can therefore interact with different proteins.
  • bag3 gene expression is constitutive for a few kinds of normal cells, including myocytes, while mutations thereof are associated with diseases of the skeletal and cardiac muscles.
  • BAG3 protein is expressed in many types of primary tumours or tumour cell lines (lymphoid or myeloid leukemias, neuroblastoma, pancreatic cancer, thyroid cancer, breast cancer and prostate cancer, melanoma, osteosarcoma, glioblastoma and tumours of the kidney, colon, ovary, etc.) (Rosati A. et al Cell Death Dis. 2011 Apr. 7; 2:e141).
  • bag3 gene expression can be induced by stressors, such as oxidants, high temperatures, lack of serum, heavy metals, HIV-1 infections, etc.
  • stressors such as oxidants, high temperatures, lack of serum, heavy metals, HIV-1 infections, etc.
  • HSF1 Heat Shock Transcription Factor
  • BAG3 protein influences cell survival in different types of cells, interacting with different molecular partners (Rosati A. et al Cell Death Dis. 2011 Apr.
  • cytoplasmic BAG3 protein has also been described in many different cellular systems and has been associated, not only with various tumours, but also in pathologies in general related to cell survival. Furthermore, patent application n. WO2011/067377 describes extracellular BAG3 protein, secreted by some cell types, as a biochemical marker in serum, which is highly specific for the diagnosis of certain pathological conditions, such as cardiac pathologies and pancreatic tumour.
  • BAG3 protein is expressed in 346/346 patients with pancreatic ductal adenocarcinoma (PDAC) and is released by the cells of the pancreatic tumour, as a soluble protein, but such protein is not expressed in either the surrounding non-neoplastic tissues or in a normal pancreas; likewise, it has been reported that the levels of BAG3 expression are related to patient survival.
  • PDAC pancreatic ductal adenocarcinoma
  • Intracellular BAG3 protein is known to maintain cardiomyocyte homeostasis and myofibrillar integrity during mechanical, proteotoxic and other types of stress; such property is related to BAG3 anti-apoptotic activity, participation in macroautophagy, and structural role in myofibrils. Therefore BAG3 defects can result in impairing cardiomyocyte survival or contractility and producing arrhythmias, dilated cardiomyopathy, or Takotsubo cardiomyopathy (C. Behl. Breaking BAG: The Co-Chaperone BAG3 in Health and Disease. Trends Pharmacol. Sci. 2016; 37:672-688).
  • Carizzo et al. (Cell Death and Disease, 2016, 7; e2431) discloses that soluble BAG3, released by stressed cardiomyocytes, has a role in regulating blood pressure levels and in modulating the vascular tone and investigate the possible hemodynamic effect of BAG3.
  • WO2015/117010A3 reports the use of composition comprising molecules that increase the intracellular expression of BAG3 and its use in the treatment of heart failure, providing evidences that the BAG3 levels are decreased in the failing heart.
  • LVEF Left Ventricular Ejection Fraction
  • BAG3 neutralization should be able to improve LVEF and therefore to preserve normal cardiac functions. This prediction appears supported by data from our laboratory.
  • fibrotic and inflammatory processes appear to be some of the integral components that causes most of the cardiac pathologies, such as angina pectoris, pre-infarction angina, myocardial infarction, heart failure, ischemia, acute coronary disease, acute heart failure, chronic heart failure and iatrogenic heart disease (Ruparella N. et al., Nature Reviews, Online 1, 2016, pp. 1-12; Gourdie R G et al., Nature, Vol. 15, 2016, pp.620-638). Furthermore, nearly all etiologies of heart disease involve pathological myocardial remodeling characterized by excessive deposition
  • ECM extracellular matrix
  • CFs cardiac fibroblasts
  • soluble BAG3 protein is understood as extra-cellular BAG3 protein, i.e. the protein secreted externally to the cell.
  • pharmaceutically acceptable excipient refers to a substance devoid of any pharmacological effect of its own and which does not produce adverse reactions when administered to a mammal, preferably a human.
  • Physiologically acceptable excipients are well known in the art and are disclosed, for instance in the Handbook of Pharmaceutical Excipients, sixth edition 2009, herein incorporated by reference.
  • spontaneous, separate or sequential administration refers to administration of the first and second compound at the same time or in such a manner that the two compound act in the patient's body at the same time or administration of one compound after the other compound in such a manner to provide a therapeutic effect.
  • the compounds are taken with a meal.
  • the compounds are taken after a meal, such as 30 minutes or 60 minutes after a meal.
  • one compound is administered to a patient for a time period followed by administration of the other compound.
  • antibody as used herein includes “fragments” or “derivatives”, which have at least one antigen binding site of the antibody and/or show the same biological activity.
  • An antibody preferably comprises at least one heavy immunoglobulin chain and at least one light immunoglobulin chain.
  • An immunoglobulin chain comprises a variable domain and optionally a constant domain.
  • a variable domain may comprise complementarity determining regions (CDRs), e.g. a CDR1, CDR2 and/or CDR3 region, and framework regions.
  • CDRs complementarity determining regions
  • humanized antibody refers to an antibody of human origin, whose hypervariable region has been replaced by the homologous region of non-human monoclonal antibodies.
  • chimeric antibody refers to an antibody containing portions derived from different antibodies.
  • recombinant antibody refers to an antibody obtained using recombinant DNA methods.
  • scFv fragment single chain variable fragment refers to immunoglobulin fragments only capable of binding with the antigen concerned. ScFv fragments can also be synthesised into dimers (diabodies), trimers (triabodies) and tetramers (tetrabodies) using peptide linkers.
  • Fab fragment (antigen-binding fragment) and “Fab2 fragment” refer to immunoglobulin fragments consisting of a light chain linked to the Fc fragment of the adjacent heavy chain, and such fragments are monovalent antibodies. When the Fab portions are in pairs, the fragment is called Fab2.
  • hybrida refers to a cell producing monoclonal antibodies.
  • monospecific antibodies refers to antibodies that all have affinity for the same antigen.
  • multispecific antibodies refers to antibodies that have affinity for several antigens.
  • bispecific antibody refers to an antibody that has affinity for two different antigens.
  • sequence identity between two polypeptide sequences, indicates the percentage of amino acids that are identical between the sequences.
  • FIG. 1 A. M-mode hearts ultrasound imaging recordings in end diastole and end systole.
  • Anti-BAG3 antibodies therefore represent a new and improved therapeutic tool for the treatment of heart diseases.
  • anti-BAG3 antibodies in this process has the surprising advantage of being more specific for the selected pathological states characterised by the over-expression and release of BAG3 protein, and also less damaging in terms of side effects.
  • One aim of the present invention is therefore the use of anti-BAG3 antibodies in the treatment of cardiovascular diseases.
  • cardiovascular diseases are selected from angina pectoris, pre-infarction angina, myocardial infarction, heart failure, ischemia, acute coronary disease, acute heart failure, chronic heart failure and iatrogenic heart disease.
  • the antibodies useable in accordance with the present invention may be either monoclonal or polyclonal antibodies, and are preferably monoclonal antibodies.
  • said monoclonal antibodies may be chosen from the following: murine antibodies, humanized antibodies, chimeric antibodies, recombinant antibodies, conjugated antibodies, scFv fragments (diabody, triabody and tetrabody), Fab fragments, and fragments F (ab′) 2.
  • the monoclonal antibodies used in the examples were obtained by immunizing mice against four distinct BAG3 protein peptides using any method known to a person skilled in the art. Such peptides were chosen because they are BAG3 protein-specific and are not shared with any other protein, including BAG proteins.
  • sequences of the four peptides are included in the BAG3 amino acid sequence (RefSeq: NP_004272; Gene ID 9531) and are selected from the following:
  • SEQ ID NO 2 SSPKSVATEERAAPS; (includes BAG3 protein amino acids 385-399);
  • SEQ ID NO 3 DKGKKNAGNAEDPHT; (includes BAG3 protein amino acids 533-547);
  • SEQ ID NO 4 NPSSMTDTPGNPAAP; (includes BAG3 protein amino acids 561-575).
  • said antibodies may be obtained by means of the Multiple Antigene Peptide approach (MAP) (Keah H H et al., J Pept Res (1988); 51: 2. Tam J P et al; Proc Natl acad Sci USA (1988), 85: 5409. Ota S, et al., Cancer Res (2002), 62: 1471), using the following map constructs:
  • MAP Multiple Antigene Peptide approach
  • said polyclonal anti-BAG3 antibodies are obtained by immunizing the animals against one of the four peptides of the sequences SEQ ID NO. 1-4 stated above.
  • the monoclonal anti-BAG3 antibodies of the present invention are obtained by means of a standard procedure (Tassone P., et al., Tissue Antigens 51: 671 (1998)) using the four MAP-BAG3 peptides described above and are produced by at least one of the nine mother clones chosen from the following: AC-1, AC-2, AC-3, AC-4, AC-5, AC-6, AC-7, AC-8, or AC-9 (described in WO03/055908), which contain specific hybridomas for each of the four MAP-BAG3 constructs used.
  • Said antibodies recognize the sequence of the four peptides of SEQ ID NO. 1-4.
  • the antibodies used are monoclonal anti-BAG3 antibodies obtained from at least one of the aforesaid mother clones, and preferably at least one chosen from the following: AC-1, AC-2, AC-3, AC-4, or AC-5. More preferably, said monoclonal antibodies are obtained from at least one mother clone chosen from the following: AC-1, AC-2, and AC-3.
  • the monoclonal anti-BAG3 antibodies envisaged in the present invention are obtained from at least one of the following clones: AC-rb1, AC-rb2, AC-rb3 and AC.rb4, and/or at least one of the following subclones: AC-rb1a, AC-rb1b, AC-rb2a, AC-rb2b, AC-rb3a, AC-rb3b, AC-rb4a, and AC-rb4b.
  • the monoclonal antibodies produced by all these clones and subclones recognize the BAG3 recombinant protein in an ELISA test.
  • said monoclonal anti-BAG3 antibodies are those that recognize epitopes in the BAG3 protein amino acid sequence, which include at least one of the following fragments: 18-33, 385-399, 533-547 or 562-575.
  • More preferably said antibodies recognize the sequence of the four peptides of SEQ ID NO. 1-4.
  • humanized anti-BAG3 antibodies are the anti-BAG3 antibodies or fragments thereof disclosed in WO2017/076878.
  • anti-BAG3 antibodies or fragments thereof usable according to the present invention are humanized antibodies which comprises:
  • sequence identity between two polypeptide sequences indicates the percentage of amino acids that are identical between the sequences, preferably over the entire length of the amino acid sequences as encoded by SEQ ID NO: 12 and SEQ ID NO: 20.
  • Preferred polypeptide sequences of the invention have a sequence identity of at least 85%, more preferably 90%, even more preferably 93%, 95%, 96%, 97%, 98% or 99%.
  • amino acid sequence having a sequence identity of at least 80% with respect to SEQ ID N. 12 is selected from SEQ ID N. 14, SEQ ID N: 16 or SEQ ID N. 18.
  • said amino acid sequence having a sequence identity of at least 80% with respect to SEQ ID N. 20 is selected from SEQ ID N. 22, SEQ ID N: 24 or SEQ ID N. 26.
  • the antibody of the present invention is the antibody wherein the heavy chain amino acid sequence is encoded by SEQ ID NO. 18 and the light chain amino acid sequence is encoded by SEQ ID NO 22 or SEQ ID N. 26.
  • the heavy chain amino acid sequence or at least the variable domain thereof or an amino acid sequence having a sequence identity of at least 80% thereof comprises the CDRs regions having the following amino acid composition: H-CDR1 comprises the amino acids GFNIKDTYMY (SEQ ID N. 5), H-CDR2 comprises the amino acids GVDPANGNTRYDPKFQG (SEQ ID N. 6), H-CDR3 comprises the amino acids DGAMDY (SEQ ID N.
  • L-CDR1 comprises the amino acids KSSQSLLYSSNQKNYLA (SEQ ID N. 8)
  • L-CDR2 comprises the amino acids WASTRES (SEQ ID N. 9)
  • L-CDR3 comprises the amino acids QQYYTYPLT (SEQ ID N. 10).
  • the heavy chain amino acid sequence or at least the variable domain thereof or an amino acid sequence having a sequence identity of at least 90% thereof comprises the CDRs regions having the following amino acid composition: H-CDR1 comprises the amino acids GFNIKDTYMY (SEQ ID N. 5), H-CDR2 comprises the amino acids GVDPANGNTRYDPKFQG (SEQ ID N. 6), H-CDR3 comprises the amino acids DGAMDY (SEQ ID N. 7) and the light chain amino acid sequence or at least the variable domain thereof or an amino acid sequence having a sequence identity of at least 90% thereof, comprises the CDRs regions having the following amino acid composition: L-CDR1 comprises the amino acids KSSQSLLYSSNQKNYLA (SEQ ID N. 8), L-CDR2 comprises the amino acids WASTRES (SEQ ID N. 9) and L-CDR3 comprises the amino acids QQYYTYPLT (SEQ ID N. 10).
  • the heavy chain amino acid sequence or at least the variable domain thereof or an amino acid sequence having a sequence identity of at least 95% thereof comprises the CDRs regions having the following amino acid composition: H-CDR1 comprises the amino acids GFNIKDTYMY (SEQ ID N. 5), H-CDR2 comprises the amino acids GVDPANGNTRYDPKFQG (SEQ ID N. 6), H-CDR3 comprises the amino acids DGAMDY (SEQ ID N.
  • L-CDR1 comprises the amino acids KSSQSLLYSSNQKNYLA (SEQ ID N. 8)
  • L-CDR2 comprises the amino acids WASTRES (SEQ ID N. 9)
  • L-CDR3 comprises the amino acids QQYYTYPLT (SEQ ID N. 10).
  • a further embodiment of the present invention is an antibody or a fragment thereof which binds to the BAG3 protein and which comprises:
  • sequence identity between two nucleotide sequences, indicates the percentage of nucleotides that are identical between the sequences, preferably over the entire length of the nucleotide sequences as encoded by SEQ ID NO: 11 and SEQ ID NO: 19.
  • Preferred nucleotide sequences of the invention have a sequence identity of at least 85%, more preferably 90%, even more preferably 93%, 95%, 96%, 97%, 98% or 99%.
  • nucleotide sequence having a sequence identity of at least 80% with respect to SEQ ID N. 11 is selected from SEQ ID N. 13, SEQ ID N: 15 or SEQ ID N. 17.
  • said amino acid sequence having a sequence identity of at least 80% with respect to SEQ ID N. 19 is selected from SEQ ID N. 21, SEQ ID N: 23 or SEQ ID N. 25.
  • the antibody of the present invention is the antibody wherein the heavy chain amino acid sequence is encoded by SEQ ID NO. 17 and the light chain amino acid sequence is encoded by SEQ ID NO 21 or SEQ ID N. 25.
  • Monoclonal antibodies may be produced by any suitable method such as that of Köhler and Milstein (1975) or by recombinant DNA methods. Monoclonal antibodies may also be isolated from phage antibody libraries using techniques described in Clackson et al. (1991).
  • Humanized forms of the antibodies may be generated according to the methods known in the art, (Kettleborough C. A. et al., 1991), such as chimerization or CDR grafting. Alternative methods for the production of humanized antibodies are well known in the art and are described in, e.g., EP 0239400 and WO 90/07861. Human antibodies can also be derived by in vitro methods. Suitable examples include but are not limited to phage display, yeast display, and the like.
  • the humanized anti-BAG3 antibodies or fragments thereof according to the present invention are obtained according to the method disclosed in WO2017/076878.
  • a further aim of the present invention is the use of the aforesaid anti-BAG3 antibodies in the treatment of a particular pathological state which involves the activation of macrophages and fibroblasts.
  • Such pathological states is a heart disease, wherein said heart disease is selected from angina pectoris, pre-infarction angina, myocardial infarction, heart failure, ischemia, acute coronary disease, acute heart failure, chronic heart failure and iatrogenic heart disease.
  • a further aim of the present invention is the use of a pharmaceutical composition comprising the aforesaid anti-BAG3 antibody in association with at least one pharmaceutically acceptable excipient in the treatment of cardiovascular diseases.
  • said cardiovascular diseases are selected from angina pectoris, pre-infarction angina, myocardial infarction, heart failure, ischemia, acute coronary disease, acute heart failure, chronic heart failure and iatrogenic heart disease.
  • composition according to the present invention can be formulated in a form suitable for oral administration or in a form suitable for parenteral or topical administration.
  • said oral form can be chosen from the following: tablets, capsules, solutions, suspensions, granules, and oily capsules.
  • said topical form can be chosen from the following: cream, ointment, ointment, solution, suspension, eye drops, pessary, nebuliser solution, spray, powder, or gel.
  • said parenteral form can be either an aqueous buffer solution or an oily suspension.
  • Said parenteral administration include administration by intramuscular, intravenous, intradermal, subcutaneous, intraperitoneal, intranodal, or intrasplenic means.
  • MI Myocardial infarct
  • C75BL/6 6 week-old mice (C75BL/6) were anesthetized by 2% isoflurane (v/v) oxygen mixture. The heart was exposed through a median sternotomy and the pericardium was opened. A 6-0 suture was placed at the apex of the LV (Left Ventricule). An 8 mm diameter cylindrical stamp was cooled in liquid nitrogen and then pressed on the LV free wall. Cryothermia was applied for 5 seconds.
  • Post-MI mice were randomized into two groups: the control group received intra-peritoneal injection of control IgG1 (20 mg/Kg) while the experimental group received 20 mg/Kg of the murine anti-BAG3 mAb in PBS. Mice were treated 3 times a week for 5 weeks.
  • echocardiography was performed 5 weeks post-MI by use of the VisualSONICS VeVo 770 imaging system with a 710 scanhead in anesthetized animals (2% isoflurane, v/v).
  • mice subjected to heart cryoinjury were reduced after five weeks, but significantly higher in animals treated with a BAG-3 neutralizing monoclonal antibody ( FIG. 1 ). Therefore the treatment with anti-BAG3 antibodies is able to reduce the inflammation and the fibrotic process in the cardiac tissue and to preserve the normal cardiac functions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
US17/040,468 2017-07-28 2018-07-26 Anti-bag3 antibodies as therapeutic reagent in cardiovascular disease Abandoned US20210024623A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IT102017000087307 2017-07-28
IT201700087307 2017-07-28
IT102017000113648 2017-10-10
IT102017000113648A IT201700113648A1 (it) 2017-10-10 2017-10-10 Anti-BAG3 antibodies as therapeutic reagent in cardiovascular diseases
PCT/EP2018/070259 WO2019020734A1 (fr) 2017-07-28 2018-07-26 Anticorps anti-bag3 utilisés en tant que réactif thérapeutique dans des maladies cardiovasculaires

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/070259 A-371-Of-International WO2019020734A1 (fr) 2017-07-28 2018-07-26 Anticorps anti-bag3 utilisés en tant que réactif thérapeutique dans des maladies cardiovasculaires

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/703,747 Division US20220213182A1 (en) 2017-07-28 2022-03-24 Anti-bag3 antibodies as therapeutic reagent in cardiovascular disease

Publications (1)

Publication Number Publication Date
US20210024623A1 true US20210024623A1 (en) 2021-01-28

Family

ID=62981261

Family Applications (2)

Application Number Title Priority Date Filing Date
US17/040,468 Abandoned US20210024623A1 (en) 2017-07-28 2018-07-26 Anti-bag3 antibodies as therapeutic reagent in cardiovascular disease
US17/703,747 Pending US20220213182A1 (en) 2017-07-28 2022-03-24 Anti-bag3 antibodies as therapeutic reagent in cardiovascular disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/703,747 Pending US20220213182A1 (en) 2017-07-28 2022-03-24 Anti-bag3 antibodies as therapeutic reagent in cardiovascular disease

Country Status (4)

Country Link
US (2) US20210024623A1 (fr)
EP (1) EP3658582A1 (fr)
CA (1) CA3107625A1 (fr)
WO (1) WO2019020734A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021140173A1 (fr) 2020-01-10 2021-07-15 Biouniversa S.R.L. Méthodes et utilisations pour le traitement de tumeurs fibreuses solides avec des inhibiteurs de bags

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1323733A1 (fr) 2001-12-28 2003-07-02 Arturo Leone Utilisation des séquences nucléotidique et protéique de BAG3 pour la recherche, le diagnostic et le traitement de maladies impliquant la mort cellulaire
IT1397083B1 (it) 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
ITMI20131351A1 (it) * 2013-08-07 2015-02-08 Biouniversa Srl Molecole leganti il recettore di bag3 per uso terapeutico.
WO2015117010A2 (fr) 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 en tant que cible pour la thérapie de l'insuffisance cardiaque
US20180296703A1 (en) * 2015-08-17 2018-10-18 Temple University Of The Commonwealth System Of Higher Education Bag3 compositions and methods
ITUB20155097A1 (it) 2015-11-05 2017-05-05 Biouniversa Srl Anticorpi umanizzati anti-BAG3

Also Published As

Publication number Publication date
WO2019020734A1 (fr) 2019-01-31
US20220213182A1 (en) 2022-07-07
EP3658582A1 (fr) 2020-06-03
CA3107625A1 (fr) 2019-01-31

Similar Documents

Publication Publication Date Title
JP4686465B2 (ja) 繊維芽細胞増殖因子レセプター−１阻害物質及びその治療方法
US20150030604A1 (en) Method of blocking vascular leakage using an anti-ang2 antibody
KR102263812B1 (ko) a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도
KR102428255B1 (ko) 위암의 검출 및 치료를 위한 조성물 및 방법
JP7334912B2 (ja) 抗プレキシンａ１アゴニスト抗体
AU2017254775A1 (en) Method of treating or preventing liver conditions
WO2021127500A9 (fr) Anticorps dirigés contre l'intégrine alpha 11 bêta 1
US20190106484A1 (en) Antibody against peptide encoded by exon-21 of periostin and pharmaceutical composition for preventing or treating inflammation-associated diseases containing the same
KR102486507B1 (ko) 플렉틴-1 결합 항체 및 그의 용도
JP2024504124A (ja) 新規の抗グレムリン１抗体
US20220213182A1 (en) Anti-bag3 antibodies as therapeutic reagent in cardiovascular disease
KR102428254B1 (ko) 난소암의 검출 및 치료를 위한 조성물 및 방법
WO2005018671A1 (fr) Inhibiteur de metastase cancereuse
KR102654035B1 (ko) 도펠 단백질 억제제
AU2018261720A1 (en) Compositions and methods related to xCT antibodies
KR20210019487A (ko) 스트레스 관련 장애 및 암의 치료를 위한 물질 및 방법
JP2021535078A (ja) 骨の疾患の治療に用いるためのトランスフェリン受容体２のアンタゴニスト及びアゴニスト
WO2022034912A1 (fr) Anticorps anti-trpv2 humain
KR101998029B1 (ko) Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도
KR102207221B1 (ko) 도펠-타겟팅 분자를 이용한 병리학적 신생혈관 생성을 억제하는 방법
WO2022130318A2 (fr) Anticorps dirigés contre l'intégrine alpha 11 bêta 1
KR20130135869A (ko) 항 단쇄 제4형 콜라겐 폴리펩타이드 항체 및 이를 포함하는 종양의 진단, 예방 또는 치료용 약제
CN116940597A (zh) 多特异性抗体及其用途
WO2019226690A1 (fr) Traitement de métastases cérébrales de mélanome par inhibition du clivage de la protéine précurseur de l'amyloïde

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

AS Assignment

Owner name: BIOUNIVERSA S.R.L., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TURCO, MARIA CATERINA;MARZULLO, LIBERATO;ROSATI, ALESSANDRA;AND OTHERS;REEL/FRAME:055152/0946

Effective date: 20210202

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: FIBROSYS S.R.L., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOUNIVERSA S.R.L.;REEL/FRAME:059604/0658

Effective date: 20220322

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION